Potential to lower treatment costs
The project also highlights Thailand’s growing capability in medical biotechnology, from genetic sequencing and bioinformatics analysis to domestic vaccine development.
If successful, local development could help reduce treatment costs by as much as four to five times compared with similar treatment expenses in Europe or the United States.
That cost difference is one of the major reasons the project is being watched closely, especially as advanced cancer therapies abroad are often expensive and difficult for many patients to access.
Still under clinical evaluation
The personalised cancer vaccine is not yet a standard treatment and remains under clinical research and evaluation.
However, the project is being seen as another important move in Thailand’s ambition to become a future hub for precision medicine.
The development also reflects a broader direction in healthcare, where treatment is increasingly shaped by each patient’s genetic and biological profile, rather than using the same approach for every case.
Patients must pass medical screening
People interested in joining the project must first be assessed under criteria set by oncology specialists from hospitals participating in the network.
Those seeking more information can contact the Government Pharmaceutical Organisation through its Google Form channel or its official LINE account.
The trial remains subject to medical evaluation, and participation depends on whether patients meet the required clinical criteria.
